What Is Bausch Health Companies Inc. (BHC) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Bausch Health Companies Inc.'s intrinsic value is estimated at a composite fair value of $16.64. At a current market price of $4.86, 7 of 9 active valuation models identify upside potential, projecting an average implied return of +242.5%. Notably, EPV sees the most upside at +451.2% (fair value: $26.79), while EROIC is the most conservative at -72.6% ($1.33). The spread between these extremes — +523.8% — reveals how different analytical frameworks can reach starkly different conclusions. Among models with highest confidence, EPV, Markov DDM lean bullish — adding weight to the bullish side of the thesis.
What Do the Models Say About BHC?
9 of 13 models are currently active for BHC. Of these, 7 models suggest upside while 2 models suggest overvaluation. The Bayesian DCF estimates BHC's intrinsic value at $26.67, implying +448.7% upside from the current price. See which stocks rank higher →
How Does BHC Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, BHC ranks #168 by Quality of Company score. CirclFi's QOC score of 5.5/10 evaluates 32 fundamental signals. A score of 5.5 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, Bausch Health Companies Inc. operates in a sector where biosimilar competition timeline is a critical driver of valuation. Investors evaluating BHC should weigh these sector-specific dynamics alongside our model-derived fair values.
Is BHC a Value Trap?
CirclFi's Value Trap algorithm assigns BHC a score of 12/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Bausch Health Companies Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Bausch Health Companies Inc. is rated at 5.5/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +523.8% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every BHC valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across BHC's 9 active models, average confidence is 49%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad